多肽新分子实体药物研发企业麦科奥特正式向港交所递交招股书。该公司专注于创新化药、多及蛋白创新生物药等前沿领域，通过将化药筛选技术与生物药研究技术深度融合，成功开发出生物大分子呼吸道给药系统Bio-Res-Deliv。该技术平台为心血管疾病、代谢性疾病及肝脏疾病等重大疾病治疗提供了创新解决方案，展现出良好的临床应用前景。此次赴港上市将为企业研发管线推进提供重要支持。
Source Link多肽新分子实体药物研发企业麦科奥特正式向港交所递交招股书。该公司专注于创新化药、多及蛋白创新生物药等前沿领域，通过将化药筛选技术与生物药研究技术深度融合，成功开发出生物大分子呼吸道给药系统Bio-Res-Deliv。该技术平台为心血管疾病、代谢性疾病及肝脏疾病等重大疾病治疗提供了创新解决方案，展现出良好的临床应用前景。此次赴港上市将为企业研发管线推进提供重要支持。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.